No 44/46 - 2026

Case of measles detected in the Capital Region of Denmark /
Iatrogenic botulism following treatment with botulinum toxin

Case of measles detected in the Capital Region of Denmark

In week 46, the Department of Clinical Microbiology (DCM) at Hvidovre Hospital and Statens Serum Institut (SSI) detected a case of measles in an adult residing in the Capital Region of Denmark.

The case is considered to be travel-related from a country in South Asia and is the first detected case in Denmark in 2026. The Danish Patient Safety Authority has been informed and has initiated the necessary contact tracing measures.

International travel significantly increases the risk of infection, and although coverage of both MMR vaccinations in the childhood vaccination programme is high, it remains important to maintain a focus on vaccination – both of children and of adults who have not previously had measles or been vaccinated.

Prevention

The most important prevention against measles is MMR vaccination. In Denmark, the MMR vaccine is offered to all children as part of the childhood vaccination programme at 15 months and 4 years of age.

There is no general recommendation to bring forward the time of vaccination, but if desired, the first dose may be given from as early as 12 months of age and still be included in the childhood vaccination programme.

Unvaccinated persons aged 18 years and over who have not had measles can receive one free MMR vaccination – without prior antibody testing. If a person has already received one MMR vaccination as a child, further vaccination is not necessary, EPI-NEWS 7-8/2024.

Management of suspected measles

For the purposes of contact tracing and the possibility of providing preventive treatment, sampling should take place as early as possible in the course of the disease. It is important that persons suspected of having measles, as far as possible, do not remain in waiting rooms with other patients, as measles is extremely contagious, Guidelines on the prevention and management of measles.

The following samples are taken when measles is suspected:

  • A throat swab and urine for detection of measles virus (morbillivirus) RNA by PCR.
  • A blood sample for determination of measles virus (morbillivirus) IgM/IgG antibodies.

As characterisation of measles virus is important for contact tracing and mapping, all suspected and confirmed measles virus-positive samples should be sent as quickly as practically possible. It is recommended to contact the virologist on call at SSI by telephone (on weekdays during daytime hours, tel. 40336379; after 15:30 and on weekends/on public holidays, the epidemiologist on call, tel. 41317404) to prepare the laboratory for the arrival of samples and thereby avoid unnecessary delays in diagnosis.

For further guidance on sampling, please refer to the diagnostic handbook, alternatively regional/local clinical microbiology guidelines and EPI-NEWS 9/2024.

Management of persons who have been exposed to measles

The Danish Patient Safety Authority identifies close contacts and ensures that they are informed about precautions and the possibility of PEP. In the event of confirmed exposure to infection – i.e. contact with a laboratory-confirmed or epidemiologically linked case – measles post-exposure prophylaxis can be given to non-immune contacts at particular risk.

The recommendations for the use of human immunoglobulin as PEP against measles were updated in 2026, EPI-NEWS 35a/2026.

Notification

Suspected measles must be notified by telephone by the treating physician to the Danish Patient Safety Authority, Supervision and Guidance East/West, EPI-NEWS 44b/2023, based on the following criteria:

  • Symptoms compatible with measles AND relevant exposure (a person in the surroundings with laboratory-confirmed measles infection or travel to an area where measles occurs)
    or
  • Symptoms compatible with measles and detection of morbillivirus IgM
    or
  • Detection of morbillivirus RNA (PCR).

Confirmed cases of measles are, in addition, subject to mandatory written notification to the Danish Patient Safety Authority, Supervision and Guidance East/West, as well as to SSI. This is done via the electronic reporting system (SEI2). See link for further information and guidance.

(J. Grau, P.H. Andersen, Department of Infectious Disease Epidemiology and Prevention, M. Pals Bendixen, B. Bødker, Department of Virology and Microbiological Preparedness, M. Helms, Hvidovre University Hospital, A. Haack Josefsen, Danish Patient Safety Authority, Supervision and Guidance East)

Iatrogenic botulism following treatment with botulinum toxin

In September 2026, the Danish Patient Safety Authority reported six cases of severe poisoning following treatment with botulinum toxin in Zealand. The patients had received treatment either for cosmetic reasons or because of excessive sweating. The treatment was presumably carried out at an unregistered cosmetic clinic or by an unauthorised practitioner. None of the six persons wishes to disclose where or by whom they were treated. It remains unknown whether the symptoms of poisoning were caused by incorrect dosing or a defect in the product itself with which the patients were treated.

Cause

Botulism is caused by botulinum toxin, which blocks the transmission of nerve signals to the muscles and can cause severe paralysis and breathing difficulties. Iatrogenic botulism can occur following therapeutic or cosmetic use of botulinum toxin as a result of systemic exposure to the toxin.

Iatrogenic botulism in Europe

In recent years, cases of iatrogenic botulism have repeatedly been reported in Europe following cosmetic and therapeutic treatment with botulinum toxin, including two larger incidents. In 2023, the European Centre for Disease Prevention and Control reported 87 cases of iatrogenic botulism among residents of five European countries associated with injections of botulinum toxin into the stomach for weight loss, performed at two private hospitals in Türkiye. In 2025, the British health authorities, the UK Health Security Agency (UKHSA), reported 42 cases of iatrogenic botulism resulting from cosmetic treatments with botulinum toxin.

The European incidents show that iatrogenic botulism occurs and can cause severe illness requiring intensive care. The actual number of cases is uncertain and may be underestimated as a result of a lack of diagnostic recognition and differences in surveillance between countries.

Symptoms and treatment

Iatrogenic botulism can cause drooping eyelids, double vision, difficulties speaking and swallowing, and progressive muscle weakness. In severe cases, muscle weakness can cause the person to have difficulty breathing. Patients are afebrile and have a normal mental state. Cerebrospinal fluid examinations and radiological examinations are also normal. Symptoms can develop from shortly after treatment to weeks after treatment with botulinum toxin, although typically between 3 and 8 days.

The diagnosis is primarily clinical. If botulism is suspected, an infectious diseases department and SSI should be consulted promptly regarding diagnostics (by telephone during daytime hours on 2016 1993) and possible antitoxin treatment (by telephone around the clock on 4131 7404).

Treatment should not be delayed while awaiting laboratory confirmation.

Unlike other forms of botulism, where faeces, tissue samples or suspected food products are examined for the presence of the bacterium Clostridium botulinum, testing serum (blood) for the toxin is the only type of patient sample suitable for testing for iatrogenic botulism. Serum is used for the mouse neutralisation test and must be collected as soon as possible after the diagnosis has been established or considered probable, and before any antitoxin treatment. However, the sensitivity of this analysis is low when used in cases of iatrogenic botulism, as the concentration of free toxin in the patient's blood is often below the detection limit of the mouse neutralisation test. For this reason, the diagnosis can be made on the basis of relevant symptoms and exposure.

Notification, etc.

Suspected cases must be notified so that the relevant authorities can follow up and prevent further cases.

  • If botulism is suspected, the case must be notified immediately by telephone to the Danish Patient Safety Authority, regardless of the presumed cause and without awaiting laboratory results.
  • If an iatrogenic cause is suspected, a notification of concern must also be submitted to the Danish Patient Safety Authority, including any information about the treating healthcare professional/clinic.
  • The telephone notification must be followed by a written notification to the Danish Patient Safety Authority and SSI using the “infectious diseases” form in SEI2.
  • If illegal manufacture, importation, distribution or other illegal handling of medicinal products is suspected, a separate report should also be submitted to the Danish Medicines Agency. Reports can be submitted via the Danish Medicines Agency's website and can also be made anonymously.

Comment

The recent Danish cases and repeated European incidents underline the need for increased awareness of iatrogenic botulism. Early recognition, notification based on clinical suspicion alone and reporting of possible illegal activities involving medicinal products are essential for patient treatment and the prevention of further cases. Members of the public who wish to receive treatment with botulinum toxin should choose a registered clinic with authorised healthcare professionals who are registered to perform the treatment.

(F. Trier Møller, L. Müller, Department of Infectious Disease Epidemiology and Prevention, A. Ronayne, Department of Bacteria, Parasites and Fungi, G. Ertner, Danish Health Authority)